Revolution Medicines reported “unprecedented” survival improvements with daraxonrasib in a Phase 3 registrational study in previously treated metastatic pancreatic ductal adenocarcinoma, setting up potential regulatory filings later this year. The company said the drug nearly doubled overall survival versus standard chemotherapy at an interim checkpoint that it then converted to final results. In the daraxonrasib arm, median overall survival was 13.2 months versus 6.7 months in the chemotherapy group, with risk of death reduced by 60% in the company’s reporting. Revolution also indicated its progression-free survival endpoints were met and that it ended the trial early after the interim readout. Separately, analysts framed the data around daraxonrasib’s RAS(ON) targeting strategy and an FDA national priority voucher that has been awarded for the program, which Revolution says could shorten review timelines. The next step is submitting the dataset for regulatory consideration and presenting at upcoming scientific meetings. For investors and clinicians, the trial adds another late-stage datapoint for the expanding RAS-targeted oncology category, where prior gains have largely been mutation- and tumor-context specific.